AngioDynamics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $16.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen’s rating is based on AngioDynamics’ strong financial performance in FY25, where the company exceeded expectations in both revenue and net loss figures. The Med Tech segment showed significant growth, particularly with products like Auryon, AngioVac, and AlphaVac, which contributed to the overall positive outlook. The company also demonstrated a solid cash position, which is expected to support its operations in the near term.
Looking ahead to FY26, AngioDynamics has provided optimistic guidance, with expectations of continued growth in the Med Tech segment and a focus on execution. The company aims to achieve positive free cash flow and maintain a strong gross margin. These factors, combined with a favorable valuation based on comparative analysis with other medical technology firms, support Yi Chen’s Buy rating and the $16 price target for the stock.
In another report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $17.00 price target.